Innovation

Development Pipeline

Development Pipeline

We are determined to drive breakthrough innovations for patients in diseases of high unmet medical need. In clinical development we are currently advancing more than 30 projects that we review regularly so that we can give priority to the most promising programs.

Pipeline Overview

The following table lists a selection of major Pharma portfolio projects that we are advancing through different stages of development.

 

More detailed information on individual programs, therapeutic areas, and development timelines as well as a one-page overview of our development portfolio can be found in our overview package for download.

 

Phasen 11 2023

Number of programs in clinical development.

 

Dr. Julia Schulze
R&D and Science - Research
Phase Area Program (Mode-of-action) Indication  
III ONC Darolutamide
(AR Inhibitor)
Prostate Cancer
(mHSPC)
Small Molecule
III ONC Darolutamide
(AR Inhibitor)
Adjuvant Prostate Cancer Small Molecule
III ONC Darolutamide
(AR Inhibitor)
Prostate Cancer with
Biochemical Recurrence after
Curative Radionuclide Therapy
Small Molecule
III CVD Finerenone
(MR Antagonist)
Heart Failure
(HFmr/pEF)
Small Molecule
III CVD Finerenone
(MR Antagonist)
Non-diabetic CKD Small Molecule
III CVD Vericiguat
(sGC Stimulator)
Heart Failure
(HFrEF)
Small Molecule
III CVD Asundexian
(FXIa Inhibitor)
Stroke Prevention in
Atrial Fibrillation
Insight Story Link
Small Molecule
III CVD Asundexian
(FXIa Inhibitor)
2 Stroke Prevention
(OCEANIC Stroke)
Small Molecule
III Other Elinzanetant
(Neurokinin-1,3 Rec Antag.)
Vasomotor Symptoms Small Molecule
III Other Aflibercept 8mg
(VEGF Inhibitor)
Retinal Vein Occlusion
(QUASAR)
Biologic_NTE
III Other Gadoquatrane
(High Relaxivity Contrast Agent)
Magnetic Resonance
Imaging (HRCA-PAT)
Contrast Agent_NTE
II ONC Regorafenib
(combi Nivolumab)
Solid tumors
(recurrent or metastatic)
Small Molecule
II CVD Asundexian
(FXIa Inhibitor)
Major Adverse Cardiac
Events Prevention
Insight Story Link
Small Molecule
II IM Zabedosertib
(IRAK4 Inhibitor)
Atopic Dermatitis
(DAMASK)
Small Molecule
II Other Runcaciguat
(sGC Activator)
Non-prolif. Diabetic
Retinopathy (NPDR)
Small Molecule
I ONC AhR Inhibitor Advanced solid tumors
Insight Story Link
Small_Molecule_NTE
I ONC mEGFR Inhibitor Advanced Non-small
Cell Lung Cancer with
EGFR Mutation and/or
HER2 Mutation
Small_Molecule_NTE
I ONC DGKzeta Inhibitor Advanced solid tumors Small_Molecule_NTE
I ONC CCR8 Ab Advanced solid tumors Antibody

I

ONC VVD Keap1 Act Cancer Small_Molecule_NTE
I ONC DGKalpha Inhibitor Cancer Small_Molecule_NTE
I ONC PSMA TAC Advanced Prostate Cancer Radiotherapy_NTE
I CVD Congestive Heart Failure
rAAV Gene Therapy
Congestive Heart Failure Gene Therapy_NTE
I CVD sGC Activator Oral Chronic Kidney Disease Small_Molecule_NTE
I CVD Anti-a2AP Acute Ischemic Stroke;
Pulmonary Embolism
Antibody
I CVD SEMA 3a Alport Syndrome Antibody
I CVD Anti-coagulant Anti-coagulation Small_Molecule_NTE
I NRD Bemdaneprocel
(Parkinson’s Disease
Cell Therapy)
Parkinson's Disease Cell Therapy_NTE
I NRD Parkinson‘s Disease
rAAV Gene Therapy
Parkinson’s Disease Gene Therapy_NTE
I NRD Multiple System Atrophy
rAAV Gene Therapy
Multiple
System Atrophy
Gene Therapy_NTE
I NRD Pompe Disease
rAAV Gene Therapy
Pompe Disease Gene Therapy_NTE
I NRD Huntington‘s Disease
rAAV Gene Therapy
Huntington‘s Disease Gene Therapy_NTE
I NRD LGMD2I/R9
rAAV Gene Therapy
Limb Girdle
Muscular Dystrophy
Gene Therapy_NTE
I Other GPR84 Antagonist Diabetic
Neuropathic Pain
Small_Molecule_NTE
I Other BAY 2701250 Pulmonary Hypertension Protein Therapeutics
0* ONC PSMA SMOL TAC Advanced Prostate Cancer Radiotherapy_NTE
0* ONC VVD STAT3 Inh Cancer Small_Molecule_NTE
0* Other Next Generation
Liver MRI
Contrast Media Contrast Agent_NTE

* Including Precision Cardiovascular, Nephrology & Acute Care

Legende_pipeline

 

New Molecular Entity   New molecular entity
Life cycle management   Life cycle management

 

Pamela Cohen
Pamela Cohen
R&D and Science - Development